Management and supportive care measures for adverse events in patients with myelodysplastic syndromes treated with azacitidine*-Reference-Cited by-同舟云学术

Management and supportive care measures for adverse events in patients with myelodysplastic syndromes treated with azacitidine*

Published:2010-04-12 Issue: Volume: Page:no-no
ISSN:0902-4441
Container-title:European Journal of Haematology
language:en
Short-container-title:

Author:

Santini Valeria,Fenaux Pierre,Mufti Ghulam J.,Hellström-Lindberg Eva,Silverman Lewis R.,List Alan,Gore Steven D.,Seymour John F.,Backstrom Jay,Beach Charles L.

Publisher

Wiley

Subject

Hematology,General Medicine

Link

http://onlinelibrary.wiley.com/wol1/doi/10.1111/j.1600-0609.2010.01456.x/fullpdf

Reference12 articles.

1. Characteristics of US patients with myelodysplastic syndromes: results of six cross-sectional physician surveys;Sekeres;J Natl Cancer Inst,2008

2. International scoring system for evaluating prognosis in myelodysplastic syndromes;Greenberg;Blood,1997

3. Randomized controlled trial of azacitidine in patients with myelodysplastic syndrome: a study of the Cancer and Leukemia Group B;Silverman;J Clin Oncol,2002

4. Impact of azacitidine on the quality of life of patients with myelodysplastic syndrome treated in a randomized phase III trial: a Cancer and Leukemia Group B study;Kornblith;J Clin Oncol,2002

5. Efficacy of azacitidine compared with conventional care regimens in higher-risk myelodysplastic syndromes: results of a randomised, phase III study;Fenaux;Lancet Oncol,2009

Cited by 100 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Infectious Complications in Patients with Myelodysplastic Syndromes: A Report from the Düsseldorf MDS Registry;Cancers;2024-02-16

2. Cytidine deaminase status as a marker of response to azacytidine treatment in MDS and AML patients;British Journal of Haematology;2023-09-10

3. How to treat VEXAS syndrome: a systematic review on effectiveness and safety of current treatment strategies;Rheumatology;2023-05-26

4. Incidence and predisposing factors of infection in patients treated with hypomethylating agents;Leukemia Research;2023-04

5. Epigenetic targeted therapies in hematological malignancies;Epigenetic Cancer Therapy;2023